|
When it comes to developing new and better biotech drugs, Biogen Idec believes two heads are better than one. The biotech giant, formed from the merger of IDEC Pharmaceuticals and Biogen, is focused on developing treatments in the areas of oncology, immunology, and neurology. Its product roster includes best-selling Avonex, the most popular drug for the treatment of relapsing multiple sclerosis; Rituxan, a monoclonal antibody developed with Genentech that treats B-cell non-Hodgkin's lymphoma (NHL) and rheumatoid arthritis; multiple sclerosis and Crohn's disease drug Tysabri; and Fumaderm, a psoriasis drug marketed in Germany. Biogen Idec serves customers in more than 90 countries.
|
| | | Contact Information | |
Address: |
14 Cambridge Center
Cambridge, MA 02142
| | Phone: | 617-679-2000 | | Fax: | 617-679-2617 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 4097.50 M | | Revenue Growth (1 yr): | 29.20% | | Employees (2007): | 4,300 | | Employee Growth (1 yr): | 14.70% |
|
|
Key People
| | • |
Chairman:
Bruce R. Ross
| | • |
President, CEO, and Director:
James C. (Jim) Mullen
| | • |
COO:
Robert A. (Bob) Hamm
|
|
|
